Discrepant nocturnal melatonin levels in monozygotic twins discordant for schizophrenia and its impact on sleep

Schizophrenia Research

Volumn 120, Issue 1-3, 2010, Pages 227-228

  Afonso, P ^a   Brissos, S ^a   Figueira, M L ^b   Paiva, T ^b  

^a Lisbon s Psychiatric Hospitalar Centre   (Portugal)

^b HOSPITAL DE SANTA MARIA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; MELATONIN; RISPERIDONE;

ACTIMETRY; ADULT; CASE REPORT; DAYTIME SOMNOLENCE; DRUG USE; HUMAN; LATENT PERIOD; LETTER; MALE; MONOZYGOTIC TWINS; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SALIVA ANALYSIS; SCHIZOPHRENIA; SITTING; SLEEP; SLEEP DISORDER; SLEEP PARAMETERS; SLEEP QUALITY; SLEEP TIME; SLEEP WAKING CYCLE; TWIN DISCORDANCE; CIRCADIAN RHYTHM; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SALIVA; TWINS;

ADULT; CIRCADIAN RHYTHM; DISEASES IN TWINS; HUMANS; MALE; MELATONIN; SALIVA; SCHIZOPHRENIA; TWINS, MONOZYGOTIC;

EID: 77954142413     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2010.03.031     Document Type: Letter

References (12)

1. Andreasen N.C., Carpenter W.T., Kane J.M., Lasser R.A., Marder S.R., Weinberger D.R. Remission in schizophrenia: proposed criteria and rationale for consensus. Am. J. Psychiatry 2005, 162(3):441-449.
2. Bersani G., Garavini A., Iannitelli A., Quartini A., Nordio M., Di Biasi C., Pancheri P. Reduced pineal volume in male patients with schizophrenia: no relationship to clinical features of the illness. Neurosci. Lett. 2002, 329(2):246-248.
3. Buisse D.J., Reynolds C.F., Monk T.H., Berman S.R., Kupfer D.J. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989, 28(2):193-213.
4. Cohrs S. Sleep disturbances in patients with schizophrenia: impact and effect of antipsychotics. CNS Drugs 2008, 22(11):939-962.
5. Monteleone P., Natale M., La Rocca A., Maj M. Decreased nocturnal secretion of melatonin in drug-free schizophrenics: no change after subchronic treatment with antipsychotics. Neuropsychobiology 1997, 36(4):159-163.
6. Monti J.M., Monti D. Sleep disturbance in schizophrenia. Int. Rev. Psychiatry. 2005, 17(4):247-253.
7. Nieto A., Nieto D. The red nucleus, the substantia nigra and the pineal gland responsible for mental illness. Int. J. Neurosci. 1987, 32(1):277-278.
8. Pacchierotti C., Iapichino S., Bossini L., Pieraccini F., Castrogiovanni P. Melatonin in psychiatric disorders: a review on the melatonin involvement in psychiatry. Front. Neuroendocrinol. 2001, 22(1):18-32.
9. Robinson S., Rosca P., Durst R., Shai U., Ghinea C., Schmidt U., Nir I. Serum melatonin levels in schizophrenic and schizoaffective hospitalized patients. Acta Psychiatr. Scand. 1991, 84(3):221-224.
10. Tandon R. Effects of atypical antipsychotics on polysomnographic measures in schizophrenia. Basic and Clinical Science of Mental and Addictive Disorders 1997, Vol. 167:219-222. Karger, Basel.
11. Viganò D., Lissoni P., Rovelli F., Roselli M.G., Malugani F., Gavazzeni C., Conti A., Maestroni G. A study of light/dark rhythm of melatonin in relation to cortisol and prolactin secretion in schizophrenia. Neuro. Endocrinol. Lett. 2001, 22(2):137-141.
12. Voultsios A., Kennaway D.J., Dawson D. Salivary melatonin as a circadian phase marker: validation and comparison to plasma melatonin. J. Biol. Rhythms. 1997, 12(5):457-466.